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INTRODUCTION
In multicentre radiotherapy clinical trials, lack of consistency in trial protocol interpretation, treatment planning and delivery can reduce the ability of the trial to generate significant results (1) (2) (3) (4) (5) (6) . Several collaborative trials groups have adopted procedures for quality assurance (QA) of treatment planning data for assessing centres' abilities to meet protocol requirements or for review of individual trial participants' plans (7, 8) . The complexity of such reviews can vary from simple visual inspection of hardcopy information (9) , to more automated reviews based on electronic submission and review systems (10-13), The importance of rigorous QA of radiotherapy was highlighted by the results of the TROG 02.02 'HeadSTART' trial for head and neck chemoradiotherapy, where it was shown that the influence of radiotherapy quality could be greater than that of the intervention being evaluated in the trial. (5) The Trans-Tasman Radiation Oncology Group (TROG) 03.04 'RADAR' (Randomised Androgen Deprivation and Radiotherapy) trial was principally aimed at evaluation of variable-duration androgen deprivation (AD) for localised prostate carcinoma. (14) The trial also examined the role of three-dimensional conformal radiation therapy (3DCRT) including dose escalation. RADAR built on the TROG 96.01 prostate trial which required a dose prescription of 66 Gy and was carried out in the era of early computed tomography (CT) planning (< 60% of plans were based on CT imaging). Late Grade 2 rectal toxicity was consistent with that reported by Pollack et al (15, 16) who demonstrated that rectal toxicity will significantly increase as the dose prescription is increased unless rectal sparing can be achieved via stringent conformal techniques. To facilitate the generation of quality data for the RADAR trial and provide a safe environment for the introduction of techniques that were novel to many centres, the technical requirements were audited through a series of complementary QA studies.
These were aimed at ensuring protocol compliance and allowed quantification of the variability between centres and participants in planning/treatment methodology. The ability of participating centres to deliver accurate radiotherapy was assessed by means of (previously published) setup accuracy (SUA) (17) and phantom-based dosimetric (18) (19) (20) (21) studies. These two studies provided a quality framework for the RADAR trial, establishing minimum requirements for spatial and dosimetric accuracy, quantifying the related underlying uncertainties and challenging contributing centres to meet the trial protocol requirements. This paper describes three additional QA activities around treatment planning which provided complementary and ongoing quality assessment during the trial. The overall influence of these activities was examined via their impact on the quality of planned radiotherapy delivery for trial participants and general radiotherapy practice at participating centres. Future publications will report on the nontechnical QA activities associated the RADAR trial.
METHODS AND MATERIALS

Trial Overview
The RADAR plans were exported from SWAN to a relational database, allowing manuallyreported treatment information to be directly linked to each treatment plan. It also allowed retrieval of plans from the database directly into SWAN, and the ability to perform operations on the stored data without requiring that it be re-imported in full.
The database can be queried using standard Structured Query Language (SQL)
operations. Functionality was incorporated to enable specific treatment fields and dosimetric parameters to be compared with protocol requirements (26 
Treatment Planning QA Exercises
Benchmarking Exercise
A benchmarking exercise ('dummy-run') was undertaken to identify ambiguities in protocol recommendations and to collect plan data in electronic format for validation of the QA process. Participation in the benchmarking exercise was encouraged, though was not mandatory for trial participation. Participating centres were asked to contour one intermediate and one high risk case (using supplied DICOM CT data) according to the protocol. In addition, sites were required to plan the high risk case to a dose of 74
Gy prescribed to the ICRU reference point (28) .
Treatment Plan Review and Post-Treatment Verification
Centres exported the electronic treatment plans for submission to the radiotherapy review team (RTRT), together with a report that ensured that reviewed data were consistent with those from the original treatment planning system (TPS). Electronic plan submission was not mandatory for patients receiving the combined EBRT/HDR boost treatment approach. All submitted EBRT plans were reviewed by an expert RTRT radiation therapist, in addition to automated review using the auto-report function in SWAN (see Table 1 ). 'Variation' of items relative to protocol were categorised as either:
• 'Minor' -outside protocol recommendations but unlikely to influence clinical outcome; The definitions of these specific to each reviewed item are provided in Table 1 .
Periodic Contour Audit
A separate QA program was developed to audit contouring practices. The audit team 
RESULTS
Benchmarking Exercise
Thirteen centres participated. For centres that did not participate, submission of data for their first accrued participant was used as an opportunity to validate the centre's ability to submit correctly formatted, complete and compliant data.
One centre submitted 5 sets of contours from 5 clinicians. Variability was seen in contouring practices particularly in the superior-inferior direction -in a coronal plane Table e1 of the supporting online material.
It has been suggested that treatment planning factors including plan complexity and patient anatomy may weigh heavily on variation rates (29) . As such, other factors were investigated for their impact on compliance as summarised in Table 2 . In order to attempt to identify which aspects of the protocol were leading to differences in variation Table 2 showing a significant difference between the groups, the entire list of review items for individual participants was reviewed in order to determine which review items most contributed to the observed difference. 
Periodic Contour Audit
DISCUSSION Benchmarking Exercise
The aim of the benchmarking exercise was to identify ambiguities in the protocol and test the plan review process prior to recruitment of a large number of participants. Based As the definition of the inferior rectum was linked to the definition of the prostatic apex, a large variability of the inferior extent of the rectum was expected. The variability in defining the superior extent was not expected, though in some cases this was because the centre had defined the superior rectum to be 15 mm above the prostate, rather than using the anatomical definition.
Overall the benchmarking exercise for this trial served to alert the RTRT that variations in contouring were likely and that centres would need to be reminded to correctly apply PTV margins and follow the protocol definition for rectal length. Generally, treatment planning complied with the protocol.
Treatment Plan Review and Post-Treatment Verification
Review of treatment plans prior to treatment was not possible for this trial as submission was on compact disk requiring postal delivery. Major variations were The SWAN system enabled multiple treatment and dosimetric parameters to be quickly assessed and passed, without transposition errors, to the trial database. The automated functionality of the system enabled multiple variables to be objectively assessed for 93% of participants treated using EBRT alone in this trial, providing reliable information on the quality of plan data submitted and a quantitative measure of protocol conformity.
The patient anatomical factors shown to impact on protocol compliance (Table 2) reflect the difficulty to meet protocol requirements with increasing prostate and rectal volumes.
The investigated treatment planning factors suggest that the use of lower beam energies, MLCs for field definition and prone patient orientation will lead to a plan of poorer quality. This is only according to the definitions within the RADAR protocol however.
These factors will be prime candidates for assessment against toxicity and progression Table 2 were not the subject of the trial and were accordingly not randomised.
The significant results displayed in Table 2 should be considered in light of potential underlying correlations with other treatment factors. For the dichotomised factors showing significant difference in mean variation rates between groups for example, it was determined that the impact of the factors 'beam energy' and 'rectal filling protocol' was due to difficulty in meeting dosimetric constraints. For the factors 'field definition'
and 'patient setup orientation' however, some main influencing review items (e.g., applied margin and immobilisation technique) would not likely be influenced by those factors and more than likely the association is simply via the contributing centre.
With 754 treatment plans stored in the SWAN database, comparing dosimetric parameters with patient outcomes will provide definitive correlation. For example, the planned rectal contours varied greatly. Using the SWAN software, rectal contours have subsequently been amended. These modified volumes will be used for correlation of a range of rectal toxicity endpoints with the dose volume relationship using analysis methods similar to those reported in the MRC RT-01 trial (32, 33) .
Periodic Contour Audit
Auditing CTV contouring practices presented a challenge for the audit team as no clear guidelines existed for the definition of major and minor protocol variations. Even among reviewers consensus of opinion was difficult to achieve. Feedback to trial centres was therefore limited to identifying outliers such as CTVs that clearly extended inferiorly into the urogenital diaphragm, which did not include the proximal seminal 
Impact of QA Program
The results of the RADAR trial are still maturing and the clinical impact of protocol non-conformity is yet to be tested. We have found that rigorous pre-trial credentialing provides an opportunity to identify and correct for systematic planning deficiencies before they have the opportunity to impact on trial outcomes. To this we add that it also provides an ideal opportunity for the development of consensus guidelines for plan review and for centres to become familiar with the plan submission process. This was certainly the experience for the RADAR trial in Australasia. than when a bulking agent is used (N = 700, mean = 7.5 %)
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• Femoral head dose constraints
• CI PTV1
• CI PTV2 • CI PTV1
• CI PTV2
• Margin applied to PTV2
• 95% coverage of PTV1
• Immobilisation device appropriate † Assessed via linear regression 
